{"ticker": {"uuid": "8e91d034-43e2-4ca2-9dbc-7dda5c530cad", "symbol": "FENC", "name": "Fennec Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Understanding the Setup: (FENC) and Scalable Risk", "summary": "This article analyzes Fennec Pharmaceuticals Inc. (FENC), highlighting conflicting sentiment across different time horizons despite a breakout underway that suggests higher levels. It details AI-generated trading strategies including position, momentum breakout, and risk hedging,", "url": "https://news.stocktradersdaily.com/news_release/101/Understanding_the_Setup:_FENC_and_Scalable_Risk_071326044202_1783975322.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T16:40:49", "published_display": "13 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Fennec (NASDAQ: FENC) ex-director exercises options, sells shares for taxes", "summary": "Fennec Pharmaceuticals Inc.'s former director, Rosty Raykov, exercised stock options for 15,597 shares and received 2,778 restricted shares. Concurrently, he sold 9,599 shares at $10.41 each to cover tax obligations. These transactions were executed on July 1, 2026, under a pre-a", "url": "https://www.stocktitan.net/sec-filings/FENC/form-4-fennec-pharmaceuticals-inc-insider-trading-activity-38e67d3c78c8.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:42:26", "published_display": "02 Jul 2026 19:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 FENNEC PHARMACEUTICALS INC. For: 1 July By Investing.com", "summary": "This article announces a Form 144 filing for FENNEC PHARMACEUTICALS INC. for July 1st, as reported by Investing.com. It also includes a disclaimer about the high risks associated with trading financial instruments and cryptocurrencies, emphasizing the volatility of markets and th", "url": "https://m.in.investing.com/news/stock-market-news/form-144-fennec-pharmaceuticals-inc-for-1-july-93CH-5479742?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-07-02T03:10:47", "published_display": "02 Jul 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FENNEC (FENC) CFO Andrade gains 1,703 vested shares, now holds 290,972", "summary": "FENNEC PHARMACEUTICALS INC. CFO Robert Andrade acquired 1,703 common shares through a grant/award acquisition at a price of $0.00 per share. These shares were released from restrictions on prior awards from May 16, 2024, and March 28, 2025. Following this transaction, Andrade dir", "url": "https://www.stocktitan.net/sec-filings/FENC/form-4-fennec-pharmaceuticals-inc-insider-trading-activity-53241449e395.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:10:21", "published_display": "01 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec (NASDAQ: FENC) Chief Strategy Officer receives 156-share stock award", "summary": "Fennec Pharmaceuticals Inc.'s Chief Strategy Officer, Christiana Marie Cioffi, received a grant of 156 common shares at no cost, which increased her direct holdings to 24,332 shares. This transaction represents the release of restrictions on stock previously awarded on March 28, ", "url": "https://www.stocktitan.net/sec-filings/FENC/form-4-fennec-pharmaceuticals-inc-insider-trading-activity-b1e305dfb133.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:10:21", "published_display": "01 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Pharmaceuticals (FENC) CCO receives 168-share award, holds 21,183", "summary": "Fennec Pharmaceuticals Chief Commercial Officer Terry L. Evans was awarded 168 common shares as part of an equity compensation plan, increasing his total direct holdings to 21,183 common shares. This transaction was not an open-market purchase but rather the release of restricted", "url": "https://www.stocktitan.net/sec-filings/FENC/form-4-fennec-pharmaceuticals-inc-insider-trading-activity-4bc453b67320.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:10:21", "published_display": "01 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Pharmaceuticals (NASDAQ: FENC) CEO reports 1,159-share award release", "summary": "Fennec Pharmaceuticals CEO Jeffrey S. Hackman reported the acquisition of 1,159 common shares on June 30, 2026. These shares were released from restrictions related to an award granted on March 28, 2025, and involve no purchase price, signaling a routine equity award release rath", "url": "https://www.stocktitan.net/sec-filings/FENC/form-4-fennec-pharmaceuticals-inc-insider-trading-activity-a11f51f7d7c5.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:10:21", "published_display": "01 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FENC (NASDAQ: FENC) plans 9,599-share option sale; prior small sales listed", "summary": "A Rule 144 SEC filing indicates that FENNC PHARMACEUTICALS INC. (NASDAQ: FENC) has a proposed sale of 9,599 common shares tied to a stock option exercise planned for July 1, 2026. The filing also lists prior dispositions by Rostislav Raykov, including 9,747 shares sold on June 1,", "url": "https://www.stocktitan.net/sec-filings/FENC/144-fennec-pharmaceuticals-inc-sec-filing-c6cdab1772b4.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:10:21", "published_display": "01 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec (NASDAQ: FENC) CMO awarded 168 shares, holds 21,183", "summary": "Fennec Pharmaceuticals' Chief Medical Officer, Pierre Sargis Sayad, reported the acquisition of 168 common shares as a compensation-related grant, with a price of $0.00 per share. These shares were released from restrictions from an award originally granted in March 2025. Followi", "url": "https://www.stocktitan.net/sec-filings/FENC/form-4-fennec-pharmaceuticals-inc-insider-trading-activity-14d65dc5de33.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:10:21", "published_display": "01 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Pharmaceuticals Inc.(NasdaqCM:FENC) dropped from Russell 2500 Value Benchmark", "summary": "Fennec Pharmaceuticals Inc. (NasdaqCM:FENC) has been removed from the Russell 2500 Value Benchmark, as well as several other Russell indices including the Russell 2000 Value, Microcap Value, 3000E Value, 3000 Value, and Small Cap Comp Value Benchmarks. The company, a commercial-s", "url": "https://www.marketscreener.com/news/fennec-pharmaceuticals-inc-nasdaqcm-fenc-dropped-from-russell-2500-value-benchmark-ce7f5fdfdf8ef325", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T11:41:01", "published_display": "29 Jun 2026 11:41", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Fennec Pharmaceuticals Inc. \u2013 NASDAQ:FENC", "summary": "The article briefly presents financial data for Fennec Pharmaceuticals Inc. (NASDAQ: FENC), specifically its enterprise value to EBITDA forward metric. It appears to be a stub or data point from a financial platform like TradingView, with no further analytical content provided be", "url": "https://www.tradingview.com/symbols/NASDAQ-FENC/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T18:39:36", "published_display": "27 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Fennec Pharmaceuticals Inc. \u2013 FWB:RV41", "summary": "This article provides forward-looking enterprise value to EBIT data for Fennec Pharmaceuticals Inc. (FWB:RV41) on the Frankfurt Stock Exchange. It highlights the availability of financial information and market data for the company on the TradingView platform.", "url": "https://www.tradingview.com/symbols/FWB-RV41/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T10:39:36", "published_display": "27 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Pharmaceuticals Inc.(NasdaqCM:FENC) dropped from Russell Small Cap Comp Value Benchmark", "summary": "Fennec Pharmaceuticals Inc. (NasdaqCM:FENC) has been removed from the Russell Small Cap Comp Value Benchmark, as well as multiple other Russell benchmarks including the Russell 2000 Value, Microcap Value, 3000E Value, 3000 Value, and 2500 Value benchmarks on June 28-29, 2026. The", "url": "https://www.marketscreener.com/news/fennec-pharmaceuticals-inc-nasdaqcm-fenc-dropped-from-russell-small-cap-comp-value-benchmark-ce7f5fdfde8ff625", "source_name": "marketscreener.com", "published_at": "2026-06-26T17:39:11", "published_display": "26 Jun 2026 17:39", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)", "summary": "Fennec Pharmaceuticals Inc. announced the grant of incentive stock option awards to a new non-executive employee to purchase 15,000 common shares. These grants, made under Nasdaq Listing Rule 5635(c)(4), are inducements for the employee's new employment. The stock options have an", "url": "https://www.theglobeandmail.com/investing/markets/stocks/FRX-T/pressreleases/2577614/fennec-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4/", "source_name": "The Globe and Mail", "published_at": "2026-06-26T15:09:48", "published_display": "26 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Fennec Pharmaceuticals Inc. \u2013 NASDAQ:FENC", "summary": "This article provides a brief snapshot of the \"Price to earnings forward\" for Fennec Pharmaceuticals Inc. (NASDAQ: FENC) from TradingView. The content is primarily a data placeholder, indicating the stock's financial overview and market information without detailed figures. It al", "url": "https://www.tradingview.com/symbols/NASDAQ-FENC/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:39:40", "published_display": "26 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Pharmaceuticals Inc. Actuals & Estimates (TSX:FRX)", "summary": "This article provides an overview of Fennec Pharmaceuticals Inc. (TSX:FRX), offering details on its current stock price, historical performance, analyst forecasts, and financial data. It covers aspects like market capitalization, volatility, earnings, revenue, and employee count,", "url": "https://www.tradingview.com/symbols/TSX-FRX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T11:41:01", "published_display": "26 Jun 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FENC Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "Fennec Pharmaceuticals Inc. (FENC) has a 1-year price target of $15.67 from 6 analysts, with a current stock price of $11.02. The stock has seen significant increases over the past week, month, and year. Analysts provide a future price forecast with a maximum estimate of $18.00 a", "url": "https://www.tradingview.com/symbols/NASDAQ-FENC/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T09:41:01", "published_display": "26 Jun 2026 09:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Fennec Pharmaceuticals Inc. \u2013 NASDAQ:FENC", "summary": "This article displays the \"Price to sales forward\" financial metric for Fennec Pharmaceuticals Inc. (NASDAQ: FENC) on TradingView. It shows the value of this metric over a specific period, along with its change and percentage change. The content also includes navigational and pla", "url": "https://www.tradingview.com/symbols/NASDAQ-FENC/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T05:11:09", "published_display": "26 Jun 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Fennec Pharmaceuticals Inc. \u2013 BOATS:FENC", "summary": "This article provides the \"Price to earnings forward\" metric for Fennec Pharmaceuticals Inc. (BOATS:FENC) as available on TradingView. It highlights that the market was closed at the time of viewing, showing no trades. The core content is a single data point within a financial pl", "url": "https://www.tradingview.com/symbols/BOATS-FENC/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T22:39:36", "published_display": "25 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Pharmaceuticals Inc. Actuals & Estimates (LS:A12A5F)", "summary": "Fennec Pharmaceuticals Inc. (A12A5F) stock is currently trading at 8.7500 EUR, showing an 8.02% increase in the past 24 hours, with analysts forecasting a price range between 11.27 EUR and 15.60 EUR. The company will release its next earnings report on August 6, 2026, and reporte", "url": "https://www.tradingview.com/symbols/LS-A12A5F/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T22:11:09", "published_display": "25 Jun 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Pharmaceuticals Inc. Actuals & Estimates (BOATS:FENC)", "summary": "This article provides financial actuals and estimates for Fennec Pharmaceuticals Inc. (FENC), including income statement, balance sheet, and cash flow data, alongside analyst price targets and historical performance. It details recent earnings, revenue figures, and upcoming earni", "url": "https://www.tradingview.com/symbols/BOATS-FENC/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T21:39:40", "published_display": "25 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A12A5F Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Fennec Pharmaceuticals Inc. (A12A5F) stock, including analyst price targets and future predictions. It details the company's current stock price, market capitalization, historical highs and lows, and upcoming earnings report. The piece also pr", "url": "https://www.tradingview.com/symbols/LS-A12A5F/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T16:11:21", "published_display": "25 Jun 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Fennec Pharmaceuticals Inc. \u2013 BOATS:FENC", "summary": "This article provides the \"Price to book forward\" financial metric for Fennec Pharmaceuticals Inc. (BOATS:FENC). It indicates that the company's market is currently closed with no trades. The information is presented within the context of TradingView's financial data and tools.", "url": "https://www.tradingview.com/symbols/BOATS-FENC/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T16:11:21", "published_display": "25 Jun 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precision Trading with Fennec Pharmaceuticals Inc. (FENC) Risk Zones", "summary": "This article analyzes Fennec Pharmaceuticals Inc. (FENC) providing AI-generated trading strategies and risk zones. Key findings include divergent sentiment indicating choppiness, a resistance test, and an exceptional risk-reward short setup. It offers specific entry, target, and ", "url": "https://news.stocktradersdaily.com/news_release/1/Precision_Trading_with_Fennec_Pharmaceuticals_Inc._FENC_Risk_Zones_062126022202_1782066122.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-22T14:10:11", "published_display": "22 Jun 2026 14:10", "sentiment": "negative", "sentiment_pct": 36, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec awards new employee 15,000 stock options at $9.06", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOMHlYQk12QXZUMDNfY2Q1Y2NOdmQtQ0l3eXcxTlZJZzktRzhEekVPQUZVb1FSbG5CdXI5MUlMN1F6ejFyOVZyLTRNazJIU2ZWUUJVY0dEQzZfSFRBOWZuem1VdjR2VUhMUHViaU9tenNoOUZTanNtbTlWTTB4aFFSLVhYZzdOdmV2SjlTbEJEak9hYTdWckU3NW10MnpYRjFrNjlROXUyMzBTX2dFRTFoM3U5ajd5eHZQUGc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Pharmaceuticals Inc (FENC) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Fennec Pharmaceuticals Inc (FENC), highlighting its current earnings forecast score of 8.33 and ranking within the Pharmaceuticals industry. Analysts have set an average price target of $14.00 for FENC, with a consensus \"Buy\" rating ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fenc/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T18:40:12", "published_display": "17 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Pharmaceuticals Inc (FENC) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Fennec Pharmaceuticals Inc's (FENC) dividend and stock split history. It indicates that FENC has not distributed any dividends over the past five years and has no recorded stock splits. The page also presents current stock pricing information ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fenc/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T09:41:24", "published_display": "17 Jun 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Pharmaceuticals Inc (FENC) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Fennec Pharmaceuticals Inc (FENC), highlighting its current price momentum score of 6.84 and its trading range between resistance at 10.17 and support at 8.23. The analysis includes a summary of various technical indicators, such as M", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fenc/technical", "source_name": "TradingKey", "published_at": "2026-06-17T07:02:32", "published_display": "17 Jun 2026 07:02", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Fennec hire gets 10,000 stock options at $9, 10-year term", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPQ1labTZQVVNmNnpBTTlReWFldHI4cnd6MzlyMHFIMEtpU05rcDRrUVdEUl9GMlEwMXJjX0pnLXJRSmozR0FMempxaDlrenFiazEzSWpxVlhVTVZCalVhVzBGUUd6TXhjc1ctOG5aMEwwQWxHN1BReTVUSDVDN1JLdjhxVjExVFJPcGhRWVJ0S2pLT3RKYnB0eks2RHNuczAwQWN4T2U1WTlpRlNYRVZIcHJySnZQS3NNYkE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Announces Results of Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/fennec-announces-results-annual-meeting-203000102.html", "source_name": "GlobeNewswire", "published_at": "2026-06-10T20:30:00+00:00", "published_display": "10 Jun 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Announces New Research Supporting Pedmark's Use at ASCO Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fennec-announces-research-supporting-pedmark-112154454.html", "source_name": "MT Newswires", "published_at": "2026-05-22T11:21:54+00:00", "published_display": "22 May 2026 11:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK\u00ae at the 2026 ASCO Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fennec-pharmaceuticals-announces-research-supporting-220100775.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T22:01:00+00:00", "published_display": "21 May 2026 22:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Three new Fennec hires get options on 50,000 shares at $9.75", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPeGRqRFRvMmpzdHd5NEw1TVFxOXVjY1RjWHpSSndPaTJaZVVxNU1Ma0hoNVBLdG5Yb2VLUE9iV1NTc282M0g3a3pPM29ma3NXU3hDajB0bDdLTC1Eai1pOTlfNUtqOEZLOFVXSnVhODV2UHQ5YzVMU1ctU09uTkt6cEctdkJRRXd1Mm5jNG9VUWZkTGE3Wld5WFZpQTJzZ3llODNpakRGWnZ4b182NFRzOEI4Rjd5a0hpWVE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Not Worried About Fennec Pharmaceuticals' (NASDAQ:FENC) Cash Burn", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Fennec Pharmaceuticals Inc (FENC) Q1 2026 Earnings Call Highlights: Record Sales Surge and ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fennec-pharmaceuticals-inc-fenc-q1-230304701.html", "source_name": "GuruFocus.com", "published_at": "2026-05-14T23:03:04+00:00", "published_display": "14 May 2026 23:03", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Pharmaceuticals Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/fdce66f2-a847-36fe-83d7-dc3ad2e3d7b6/fennec-pharmaceuticals-inc..html", "source_name": "Moby", "published_at": "2026-05-14T21:11:37+00:00", "published_display": "14 May 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FENNEC PHARMACEUTICALS ($FENC) Releases Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQU2ZscWJ5YTdhSjhBZUVGbnN0WWdyUG9nWHA1WS12c2dLT3N2aWxMSnp1WWIwZTdfN3VuR21JMTNnZGxDNWZwNmdWcW9OTU1kRjRGdHEtS2p0S3JHQTdyVHdadURfd1J2NVZiNTgzdk5sU1V1OWpFc2hyN280OXcxMS1OdWVrNXhvNmplUUJzRkJMZjg?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Fennec Pharmaceuticals (FENC) Quarterly Loss Near Breakeven Challenges Bearish Profitability Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Pharmaceuticals (FENC) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE54dW05RndfdEpaeUdwZU1Dd3Uzalh1a2VuTUl1LTdOTFNlRmdGbVVSRkRTQmt4eVlNMEZaSDJEYzdfeW9sME5Kc2FMemQ0OVo4LUtz?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:23:55+00:00", "published_display": "25 Apr 2025 00:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Understanding the Setup: (FENC) and Scalable Risk", "summary": "This article analyzes Fennec Pharmaceuticals Inc. (FENC), highlighting conflicting sentiment across different time horizons despite a breakout underway that suggests higher levels. It details AI-generated trading strategies including position, momentum breakout, and risk hedging,", "url": "https://news.stocktradersdaily.com/news_release/101/Understanding_the_Setup:_FENC_and_Scalable_Risk_071326044202_1783975322.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T16:40:49", "published_display": "13 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec (NASDAQ: FENC) ex-director exercises options, sells shares for taxes", "summary": "Fennec Pharmaceuticals Inc.'s former director, Rosty Raykov, exercised stock options for 15,597 shares and received 2,778 restricted shares. Concurrently, he sold 9,599 shares at $10.41 each to cover tax obligations. These transactions were executed on July 1, 2026, under a pre-a", "url": "https://www.stocktitan.net/sec-filings/FENC/form-4-fennec-pharmaceuticals-inc-insider-trading-activity-38e67d3c78c8.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:42:26", "published_display": "02 Jul 2026 19:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 FENNEC PHARMACEUTICALS INC. For: 1 July By Investing.com", "summary": "This article announces a Form 144 filing for FENNEC PHARMACEUTICALS INC. for July 1st, as reported by Investing.com. It also includes a disclaimer about the high risks associated with trading financial instruments and cryptocurrencies, emphasizing the volatility of markets and th", "url": "https://m.in.investing.com/news/stock-market-news/form-144-fennec-pharmaceuticals-inc-for-1-july-93CH-5479742?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-07-02T03:10:47", "published_display": "02 Jul 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FENNEC (FENC) CFO Andrade gains 1,703 vested shares, now holds 290,972", "summary": "FENNEC PHARMACEUTICALS INC. CFO Robert Andrade acquired 1,703 common shares through a grant/award acquisition at a price of $0.00 per share. These shares were released from restrictions on prior awards from May 16, 2024, and March 28, 2025. Following this transaction, Andrade dir", "url": "https://www.stocktitan.net/sec-filings/FENC/form-4-fennec-pharmaceuticals-inc-insider-trading-activity-53241449e395.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:10:21", "published_display": "01 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec (NASDAQ: FENC) Chief Strategy Officer receives 156-share stock award", "summary": "Fennec Pharmaceuticals Inc.'s Chief Strategy Officer, Christiana Marie Cioffi, received a grant of 156 common shares at no cost, which increased her direct holdings to 24,332 shares. This transaction represents the release of restrictions on stock previously awarded on March 28, ", "url": "https://www.stocktitan.net/sec-filings/FENC/form-4-fennec-pharmaceuticals-inc-insider-trading-activity-b1e305dfb133.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:10:21", "published_display": "01 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Pharmaceuticals (FENC) CCO receives 168-share award, holds 21,183", "summary": "Fennec Pharmaceuticals Chief Commercial Officer Terry L. Evans was awarded 168 common shares as part of an equity compensation plan, increasing his total direct holdings to 21,183 common shares. This transaction was not an open-market purchase but rather the release of restricted", "url": "https://www.stocktitan.net/sec-filings/FENC/form-4-fennec-pharmaceuticals-inc-insider-trading-activity-4bc453b67320.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:10:21", "published_display": "01 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Pharmaceuticals (NASDAQ: FENC) CEO reports 1,159-share award release", "summary": "Fennec Pharmaceuticals CEO Jeffrey S. Hackman reported the acquisition of 1,159 common shares on June 30, 2026. These shares were released from restrictions related to an award granted on March 28, 2025, and involve no purchase price, signaling a routine equity award release rath", "url": "https://www.stocktitan.net/sec-filings/FENC/form-4-fennec-pharmaceuticals-inc-insider-trading-activity-a11f51f7d7c5.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:10:21", "published_display": "01 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FENC (NASDAQ: FENC) plans 9,599-share option sale; prior small sales listed", "summary": "A Rule 144 SEC filing indicates that FENNC PHARMACEUTICALS INC. (NASDAQ: FENC) has a proposed sale of 9,599 common shares tied to a stock option exercise planned for July 1, 2026. The filing also lists prior dispositions by Rostislav Raykov, including 9,747 shares sold on June 1,", "url": "https://www.stocktitan.net/sec-filings/FENC/144-fennec-pharmaceuticals-inc-sec-filing-c6cdab1772b4.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:10:21", "published_display": "01 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec (NASDAQ: FENC) CMO awarded 168 shares, holds 21,183", "summary": "Fennec Pharmaceuticals' Chief Medical Officer, Pierre Sargis Sayad, reported the acquisition of 168 common shares as a compensation-related grant, with a price of $0.00 per share. These shares were released from restrictions from an award originally granted in March 2025. Followi", "url": "https://www.stocktitan.net/sec-filings/FENC/form-4-fennec-pharmaceuticals-inc-insider-trading-activity-14d65dc5de33.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:10:21", "published_display": "01 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Pharmaceuticals Inc.(NasdaqCM:FENC) dropped from Russell 2500 Value Benchmark", "summary": "Fennec Pharmaceuticals Inc. (NasdaqCM:FENC) has been removed from the Russell 2500 Value Benchmark, as well as several other Russell indices including the Russell 2000 Value, Microcap Value, 3000E Value, 3000 Value, and Small Cap Comp Value Benchmarks. The company, a commercial-s", "url": "https://www.marketscreener.com/news/fennec-pharmaceuticals-inc-nasdaqcm-fenc-dropped-from-russell-2500-value-benchmark-ce7f5fdfdf8ef325", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T11:41:01", "published_display": "29 Jun 2026 11:41", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Fennec Pharmaceuticals Inc. \u2013 NASDAQ:FENC", "summary": "The article briefly presents financial data for Fennec Pharmaceuticals Inc. (NASDAQ: FENC), specifically its enterprise value to EBITDA forward metric. It appears to be a stub or data point from a financial platform like TradingView, with no further analytical content provided be", "url": "https://www.tradingview.com/symbols/NASDAQ-FENC/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T18:39:36", "published_display": "27 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Fennec Pharmaceuticals Inc. \u2013 FWB:RV41", "summary": "This article provides forward-looking enterprise value to EBIT data for Fennec Pharmaceuticals Inc. (FWB:RV41) on the Frankfurt Stock Exchange. It highlights the availability of financial information and market data for the company on the TradingView platform.", "url": "https://www.tradingview.com/symbols/FWB-RV41/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T10:39:36", "published_display": "27 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Pharmaceuticals Inc.(NasdaqCM:FENC) dropped from Russell Small Cap Comp Value Benchmark", "summary": "Fennec Pharmaceuticals Inc. (NasdaqCM:FENC) has been removed from the Russell Small Cap Comp Value Benchmark, as well as multiple other Russell benchmarks including the Russell 2000 Value, Microcap Value, 3000E Value, 3000 Value, and 2500 Value benchmarks on June 28-29, 2026. The", "url": "https://www.marketscreener.com/news/fennec-pharmaceuticals-inc-nasdaqcm-fenc-dropped-from-russell-small-cap-comp-value-benchmark-ce7f5fdfde8ff625", "source_name": "marketscreener.com", "published_at": "2026-06-26T17:39:11", "published_display": "26 Jun 2026 17:39", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)", "summary": "Fennec Pharmaceuticals Inc. announced the grant of incentive stock option awards to a new non-executive employee to purchase 15,000 common shares. These grants, made under Nasdaq Listing Rule 5635(c)(4), are inducements for the employee's new employment. The stock options have an", "url": "https://www.theglobeandmail.com/investing/markets/stocks/FRX-T/pressreleases/2577614/fennec-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4/", "source_name": "The Globe and Mail", "published_at": "2026-06-26T15:09:48", "published_display": "26 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Fennec Pharmaceuticals Inc. \u2013 NASDAQ:FENC", "summary": "This article provides a brief snapshot of the \"Price to earnings forward\" for Fennec Pharmaceuticals Inc. (NASDAQ: FENC) from TradingView. The content is primarily a data placeholder, indicating the stock's financial overview and market information without detailed figures. It al", "url": "https://www.tradingview.com/symbols/NASDAQ-FENC/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:39:40", "published_display": "26 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Pharmaceuticals Inc. Actuals & Estimates (TSX:FRX)", "summary": "This article provides an overview of Fennec Pharmaceuticals Inc. (TSX:FRX), offering details on its current stock price, historical performance, analyst forecasts, and financial data. It covers aspects like market capitalization, volatility, earnings, revenue, and employee count,", "url": "https://www.tradingview.com/symbols/TSX-FRX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T11:41:01", "published_display": "26 Jun 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FENC Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "Fennec Pharmaceuticals Inc. (FENC) has a 1-year price target of $15.67 from 6 analysts, with a current stock price of $11.02. The stock has seen significant increases over the past week, month, and year. Analysts provide a future price forecast with a maximum estimate of $18.00 a", "url": "https://www.tradingview.com/symbols/NASDAQ-FENC/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T09:41:01", "published_display": "26 Jun 2026 09:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Fennec Pharmaceuticals Inc. \u2013 NASDAQ:FENC", "summary": "This article displays the \"Price to sales forward\" financial metric for Fennec Pharmaceuticals Inc. (NASDAQ: FENC) on TradingView. It shows the value of this metric over a specific period, along with its change and percentage change. The content also includes navigational and pla", "url": "https://www.tradingview.com/symbols/NASDAQ-FENC/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T05:11:09", "published_display": "26 Jun 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Fennec Pharmaceuticals Inc. \u2013 BOATS:FENC", "summary": "This article provides the \"Price to earnings forward\" metric for Fennec Pharmaceuticals Inc. (BOATS:FENC) as available on TradingView. It highlights that the market was closed at the time of viewing, showing no trades. The core content is a single data point within a financial pl", "url": "https://www.tradingview.com/symbols/BOATS-FENC/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T22:39:36", "published_display": "25 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Pharmaceuticals Inc. Actuals & Estimates (LS:A12A5F)", "summary": "Fennec Pharmaceuticals Inc. (A12A5F) stock is currently trading at 8.7500 EUR, showing an 8.02% increase in the past 24 hours, with analysts forecasting a price range between 11.27 EUR and 15.60 EUR. The company will release its next earnings report on August 6, 2026, and reporte", "url": "https://www.tradingview.com/symbols/LS-A12A5F/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T22:11:09", "published_display": "25 Jun 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Pharmaceuticals Inc. Actuals & Estimates (BOATS:FENC)", "summary": "This article provides financial actuals and estimates for Fennec Pharmaceuticals Inc. (FENC), including income statement, balance sheet, and cash flow data, alongside analyst price targets and historical performance. It details recent earnings, revenue figures, and upcoming earni", "url": "https://www.tradingview.com/symbols/BOATS-FENC/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T21:39:40", "published_display": "25 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A12A5F Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Fennec Pharmaceuticals Inc. (A12A5F) stock, including analyst price targets and future predictions. It details the company's current stock price, market capitalization, historical highs and lows, and upcoming earnings report. The piece also pr", "url": "https://www.tradingview.com/symbols/LS-A12A5F/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T16:11:21", "published_display": "25 Jun 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Fennec Pharmaceuticals Inc. \u2013 BOATS:FENC", "summary": "This article provides the \"Price to book forward\" financial metric for Fennec Pharmaceuticals Inc. (BOATS:FENC). It indicates that the company's market is currently closed with no trades. The information is presented within the context of TradingView's financial data and tools.", "url": "https://www.tradingview.com/symbols/BOATS-FENC/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T16:11:21", "published_display": "25 Jun 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precision Trading with Fennec Pharmaceuticals Inc. (FENC) Risk Zones", "summary": "This article analyzes Fennec Pharmaceuticals Inc. (FENC) providing AI-generated trading strategies and risk zones. Key findings include divergent sentiment indicating choppiness, a resistance test, and an exceptional risk-reward short setup. It offers specific entry, target, and ", "url": "https://news.stocktradersdaily.com/news_release/1/Precision_Trading_with_Fennec_Pharmaceuticals_Inc._FENC_Risk_Zones_062126022202_1782066122.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-22T14:10:11", "published_display": "22 Jun 2026 14:10", "sentiment": "negative", "sentiment_pct": 36, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec awards new employee 15,000 stock options at $9.06", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOMHlYQk12QXZUMDNfY2Q1Y2NOdmQtQ0l3eXcxTlZJZzktRzhEekVPQUZVb1FSbG5CdXI5MUlMN1F6ejFyOVZyLTRNazJIU2ZWUUJVY0dEQzZfSFRBOWZuem1VdjR2VUhMUHViaU9tenNoOUZTanNtbTlWTTB4aFFSLVhYZzdOdmV2SjlTbEJEak9hYTdWckU3NW10MnpYRjFrNjlROXUyMzBTX2dFRTFoM3U5ajd5eHZQUGc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Pharmaceuticals Inc (FENC) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Fennec Pharmaceuticals Inc (FENC), highlighting its current earnings forecast score of 8.33 and ranking within the Pharmaceuticals industry. Analysts have set an average price target of $14.00 for FENC, with a consensus \"Buy\" rating ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fenc/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T18:40:12", "published_display": "17 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Pharmaceuticals Inc (FENC) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Fennec Pharmaceuticals Inc's (FENC) dividend and stock split history. It indicates that FENC has not distributed any dividends over the past five years and has no recorded stock splits. The page also presents current stock pricing information ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fenc/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T09:41:24", "published_display": "17 Jun 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Pharmaceuticals Inc (FENC) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Fennec Pharmaceuticals Inc (FENC), highlighting its current price momentum score of 6.84 and its trading range between resistance at 10.17 and support at 8.23. The analysis includes a summary of various technical indicators, such as M", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fenc/technical", "source_name": "TradingKey", "published_at": "2026-06-17T07:02:32", "published_display": "17 Jun 2026 07:02", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Fennec hire gets 10,000 stock options at $9, 10-year term", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPQ1labTZQVVNmNnpBTTlReWFldHI4cnd6MzlyMHFIMEtpU05rcDRrUVdEUl9GMlEwMXJjX0pnLXJRSmozR0FMempxaDlrenFiazEzSWpxVlhVTVZCalVhVzBGUUd6TXhjc1ctOG5aMEwwQWxHN1BReTVUSDVDN1JLdjhxVjExVFJPcGhRWVJ0S2pLT3RKYnB0eks2RHNuczAwQWN4T2U1WTlpRlNYRVZIcHJySnZQS3NNYkE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Announces Results of Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/fennec-announces-results-annual-meeting-203000102.html", "source_name": "GlobeNewswire", "published_at": "2026-06-10T20:30:00+00:00", "published_display": "10 Jun 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Announces New Research Supporting Pedmark's Use at ASCO Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fennec-announces-research-supporting-pedmark-112154454.html", "source_name": "MT Newswires", "published_at": "2026-05-22T11:21:54+00:00", "published_display": "22 May 2026 11:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK\u00ae at the 2026 ASCO Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fennec-pharmaceuticals-announces-research-supporting-220100775.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T22:01:00+00:00", "published_display": "21 May 2026 22:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Three new Fennec hires get options on 50,000 shares at $9.75", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPeGRqRFRvMmpzdHd5NEw1TVFxOXVjY1RjWHpSSndPaTJaZVVxNU1Ma0hoNVBLdG5Yb2VLUE9iV1NTc282M0g3a3pPM29ma3NXU3hDajB0bDdLTC1Eai1pOTlfNUtqOEZLOFVXSnVhODV2UHQ5YzVMU1ctU09uTkt6cEctdkJRRXd1Mm5jNG9VUWZkTGE3Wld5WFZpQTJzZ3llODNpakRGWnZ4b182NFRzOEI4Rjd5a0hpWVE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Not Worried About Fennec Pharmaceuticals' (NASDAQ:FENC) Cash Burn", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Pharmaceuticals Inc (FENC) Q1 2026 Earnings Call Highlights: Record Sales Surge and ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fennec-pharmaceuticals-inc-fenc-q1-230304701.html", "source_name": "GuruFocus.com", "published_at": "2026-05-14T23:03:04+00:00", "published_display": "14 May 2026 23:03", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Pharmaceuticals Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/fdce66f2-a847-36fe-83d7-dc3ad2e3d7b6/fennec-pharmaceuticals-inc..html", "source_name": "Moby", "published_at": "2026-05-14T21:11:37+00:00", "published_display": "14 May 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FENNEC PHARMACEUTICALS ($FENC) Releases Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQU2ZscWJ5YTdhSjhBZUVGbnN0WWdyUG9nWHA1WS12c2dLT3N2aWxMSnp1WWIwZTdfN3VuR21JMTNnZGxDNWZwNmdWcW9OTU1kRjRGdHEtS2p0S3JHQTdyVHdadURfd1J2NVZiNTgzdk5sU1V1OWpFc2hyN280OXcxMS1OdWVrNXhvNmplUUJzRkJMZjg?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Pharmaceuticals (FENC) Quarterly Loss Near Breakeven Challenges Bearish Profitability Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fennec Pharmaceuticals (FENC) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE54dW05RndfdEpaeUdwZU1Dd3Uzalh1a2VuTUl1LTdOTFNlRmdGbVVSRkRTQmt4eVlNMEZaSDJEYzdfeW9sME5Kc2FMemQ0OVo4LUtz?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:23:55+00:00", "published_display": "25 Apr 2025 00:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 88, "total_relevant": 48, "sentiment_summary": {"positive": 8, "negative": 5, "neutral": 35, "score": 51, "total": 48, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 11.55, "count": 21}, {"event": "earnings", "label": "Earnings", "weight": 9.21, "count": 19}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 8, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 10.5, "latest_week": "2026-07-17", "one_week_move": 0.1, "four_week_move": 15.9, "twelve_week_move": 53.5, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.190562, "market_dynamics_buy_signal": false, "relative_strength": 13.902511, "fair_value_gap": 37.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 48.0984, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.1% over one week, +15.9% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 48, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 12}, {"label": "Stock Titan", "count": 11}, {"label": "Market source", "count": 6}, {"label": "simplywall.st", "count": 4}, {"label": "TradingKey", "count": 3}, {"label": "Stock Traders Daily", "count": 2}, {"label": "GlobeNewswire", "count": 2}, {"label": "Investing.com India", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 39}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 21}, {"label": "Earnings", "count": 19}, {"label": "Deals and strategy", "count": 3}, {"label": "Analyst action", "count": 2}, {"label": "Guidance", "count": 1}, {"label": "Capital return", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "39", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+0.1% over one week, +15.9% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Understanding the Setup: (FENC) and Scalable Risk"}], "updated_at": "2026-07-22T09:41:49.766346+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}